{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:40:04Z","timestamp":1792176004452,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T00:00:00Z","timestamp":1371513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s40265-013-0068-5","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T09:40:52Z","timestamp":1371462052000},"page":"1055-1066","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy and Safety of Botulinum Toxin A Intradetrusor Injections in Adults with Neurogenic Detrusor Overactivity\/Neurogenic Overactive Bladder: A Systematic Review"],"prefix":"10.1007","volume":"73","author":[{"given":"Irina","family":"Soljanik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,18]]},"reference":[{"key":"68_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37\u201349.","journal-title":"Urology"},{"key":"68_CR2","unstructured":"Pannek J, Blok B, Castro-Diaz D, et al. Guidelines on neurogenic lower urinary tract dysfunction. In: Online Guidelines. European Association of Urology. 2013. http:\/\/www.uroweb.org\/gls\/pdf\/20_Neurogenic%20LUTD_LR.pdf . Accessed Mar 2011."},{"key":"68_CR3","volume-title":"Das Fettgift oder die Fetts\u00e4ure und ihre Wirkungen auf den tierischen Organismus, ein Beitrag zur Untersuchung des in verdorbenen W\u00fcrsten giftig wirkenden Stoffes","author":"J Kerner","year":"1822","unstructured":"Kerner J. Das Fettgift oder die Fetts\u00e4ure und ihre Wirkungen auf den tierischen Organismus, ein Beitrag zur Untersuchung des in verdorbenen W\u00fcrsten giftig wirkenden Stoffes. Stuttgart: Cotta; 1822."},{"key":"68_CR4","first-page":"1","volume":"26","author":"E Ermengem van","year":"1897","unstructured":"van Ermengem E. Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Zeitsch Hyg Infekt. 1897;26:1\u201356.","journal-title":"Zeitsch Hyg Infekt"},{"issue":"Suppl 1","key":"68_CR5","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1046\/j.1526-4610.43.7s.4.x","volume":"43","author":"O Dolly","year":"2003","unstructured":"Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43(Suppl 1):S16\u201324.","journal-title":"Headache"},{"key":"68_CR6","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","volume":"185","author":"S Herschorn","year":"2011","unstructured":"Herschorn S, Gajewski J, Ethans K, et al. Efficacy of botulinum toxin a injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229\u201335.","journal-title":"J Urol"},{"key":"68_CR7","author":"Y Ikeda","year":"2012","unstructured":"Ikeda Y, Zabbarova IV, Birder LA, et al. Botulinum neurotoxin serotype a suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Eur Urol. 2012. doi: 10.1016\/j.eururo.2012.03.031 .","journal-title":"Eur Urol"},{"key":"68_CR8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","volume":"174","author":"B Schurch","year":"2005","unstructured":"Schurch B, de S\u00e8ze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196\u2013200.","journal-title":"J Urol"},{"key":"68_CR9","first-page":"24","volume":"71","author":"DD Dykstra","year":"1990","unstructured":"Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990;71:24\u20136.","journal-title":"Arch Phys Med Rehabil"},{"key":"68_CR10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/(SICI)1520-6777(1999)18:2<139::AID-NAU9>3.0.CO;2-U","volume":"18","author":"M Stohrer","year":"1999","unstructured":"Stohrer M, Schurch B, Kramer G, et al. Botulinum A toxin in the treatment of detrusor hyperreflexia in spinal cord injury: a new alternative to medical and surgical procedures? Neurourol Urodyn. 1999;18:401\u20132.","journal-title":"Neurourol Urodyn"},{"key":"68_CR11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","volume":"164","author":"B Schurch","year":"2000","unstructured":"Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692\u20137.","journal-title":"J Urol"},{"key":"68_CR12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0302-2838(03)00250-1","volume":"44","author":"T Leippold","year":"2003","unstructured":"Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol. 2003;44:165\u201374.","journal-title":"Eur Urol"},{"key":"68_CR13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","volume":"53","author":"G Karsenty","year":"2008","unstructured":"Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53:275\u201387.","journal-title":"Eur Urol"},{"key":"68_CR14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","volume":"60","author":"A Mangera","year":"2011","unstructured":"Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60:784\u201395.","journal-title":"Eur Urol"},{"key":"68_CR15","doi-asserted-by":"crossref","unstructured":"Duthie JB, Vincent M, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011;(12):CD005493.","DOI":"10.1002\/14651858.CD005493.pub3"},{"key":"68_CR16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","volume":"55","author":"A Apostolidis","year":"2009","unstructured":"Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55:100\u201320.","journal-title":"Eur Urol"},{"key":"68_CR17","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131\u20139.","journal-title":"J Urol"},{"key":"68_CR18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60:742\u201350.","journal-title":"Eur Urol"},{"key":"68_CR19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00345-009-0466-1","volume":"28","author":"B Wefer","year":"2010","unstructured":"Wefer B, Ehlken B, Bremer J, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World J Urol. 2010;28:385\u201390.","journal-title":"World J Urol"},{"key":"68_CR20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","volume":"45","author":"A Reitz","year":"2004","unstructured":"Reitz A, St\u00f6hrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45:510\u20135.","journal-title":"Eur Urol"},{"key":"68_CR21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/00365590410015867","volume":"38","author":"P Bagi","year":"2004","unstructured":"Bagi P, Biering-S\u00f8rensen F. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol. 2004;38:495\u20138.","journal-title":"Scand J Urol Nephrol"},{"key":"68_CR22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2008.08.048","volume":"55","author":"A Giannantoni","year":"2009","unstructured":"Giannantoni A, Mearini E, Del Zingaro M, et al. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol. 2009;55:705\u201311.","journal-title":"Eur Urol"},{"key":"68_CR23","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.juro.2010.08.028","volume":"184","author":"TA Abdel-Meguid","year":"2010","unstructured":"Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder\u2014to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol. 2010;184:2423\u20138.","journal-title":"J Urol"},{"key":"68_CR24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.ju.0000132152.53532.5d","volume":"172","author":"A Giannantoni","year":"2004","unstructured":"Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004;172:240\u20133.","journal-title":"J Urol"},{"key":"68_CR25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1590\/S1677-55382010000100011","volume":"36","author":"CM Gomes","year":"2010","unstructured":"Gomes CM, Castro Filho JE, Rejowski RF, et al. Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity. Int Braz J Urol. 2010;36:66\u201374.","journal-title":"Int Braz J Urol"},{"key":"68_CR26","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1464-410X.2009.08466.x","volume":"104","author":"J Grosse","year":"2009","unstructured":"Grosse J, Kramer G, Jakse G. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study. BJU Int. 2009;104:651\u20136.","journal-title":"BJU Int"},{"key":"68_CR27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2005.11.006","volume":"49","author":"V Kalsi","year":"2006","unstructured":"Kalsi V, Popat RB, Apostolidis A, et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol. 2006;49:519\u201327.","journal-title":"Eur Urol"},{"key":"68_CR28","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/nau.21146","volume":"30","author":"HC Kuo","year":"2011","unstructured":"Kuo HC, Liu SH. Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries. Neurourol Urodyn. 2011;30:1541\u20135.","journal-title":"Neurourol Urodyn"},{"key":"68_CR29","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.urology.2008.04.026","volume":"72","author":"HC Kuo","year":"2008","unstructured":"Kuo HC. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection. Urology. 2008;72:1056\u201360.","journal-title":"Urology"},{"key":"68_CR30","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1468-1331.2011.03618.x","volume":"19","author":"A Conte","year":"2012","unstructured":"Conte A, Giannantoni A, Proietti S, et al. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity. Eur J Neurol. 2012;19:725\u201332.","journal-title":"Eur J Neurol"},{"key":"68_CR31","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/S0022-5347(06)00258-8","volume":"175","author":"A Giannantoni","year":"2006","unstructured":"Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol. 2006;175:2341\u20134.","journal-title":"J Urol"},{"key":"68_CR32","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01.ju.0000169480.43557.31","volume":"174","author":"R Popat","year":"2005","unstructured":"Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005;174:984\u20139.","journal-title":"J Urol"},{"key":"68_CR33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.47102\/annals-acadmedsg.V36N1p11","volume":"36","author":"AM Tow","year":"2007","unstructured":"Tow AM, Toh KL, Chan SP, et al. Botulinum toxin type A for refractory neurogenic detrusor overactivity in spinal cord injured patients in Singapore. Ann Acad Med Singap. 2007;36:11\u20137.","journal-title":"Ann Acad Med Singap"},{"key":"68_CR34","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.juro.2010.07.034","volume":"184","author":"SN Datta","year":"2010","unstructured":"Datta SN, Roosen A, Pullen A, et al. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol. 2010;184:2578\u201385.","journal-title":"J Urol"},{"key":"68_CR35","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/j.1464-410X.2009.08600.x","volume":"104","author":"J Pannek","year":"2009","unstructured":"Pannek J, G\u00f6cking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int. 2009;104:1246\u201350.","journal-title":"BJU Int"},{"key":"68_CR36","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1590\/S1677-55382011000500012","volume":"37","author":"S Deffontaines-Rufin","year":"2011","unstructured":"Deffontaines-Rufin S, Weil M, Verollet D, et al. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol. 2011;37:642\u20138.","journal-title":"Int Braz J Urol"},{"key":"68_CR37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00345-007-0208-1","volume":"25","author":"M Huwyler","year":"2007","unstructured":"Huwyler M, Schurch B, Knapp PA, et al. Can the ice-water test predict the outcome of intradetrusor injections of botulinum toxin in patients with neurogenic bladder dysfunction? World J Urol. 2007;25:613\u20137.","journal-title":"World J Urol"},{"key":"68_CR38","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.eururo.2007.08.052","volume":"52","author":"A Reitz","year":"2007","unstructured":"Reitz A, Denys P, Fermanian C, et al. Do repeat intradetrusorbotulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol. 2007;52:1729\u201335.","journal-title":"Eur Urol"},{"key":"68_CR39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/nau.20153","volume":"25","author":"H Schulte-Baukloh","year":"2006","unstructured":"Schulte-Baukloh H, Schobert J, Stolze T, et al. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn. 2006;25:110\u20135.","journal-title":"Neurourol Urodyn"},{"key":"68_CR40","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/j.1464-410X.2011.10639.x","volume":"109","author":"R Caremel","year":"2012","unstructured":"Caremel R, Courtois F, Charvier K, et al. Side effects of intradetrusorbotulinum toxin injections on ejaculation and fertility in men with spinal cord injury: preliminary findings. BJU Int. 2012;109:1698\u2013702.","journal-title":"BJU Int"},{"key":"68_CR41","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/j.1464-410X.2010.09435.x","volume":"106","author":"S Mouttalib","year":"2010","unstructured":"Mouttalib S, Khan S, Castel-Lacanal E, et al. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU Int. 2010;106:1677\u201380.","journal-title":"BJU Int"},{"key":"68_CR42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.sc.3101318","volume":"40","author":"JJ Wyndaele","year":"2002","unstructured":"Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002;40:599\u2013600.","journal-title":"Spinal Cord"},{"key":"68_CR43","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.juro.2010.12.002","volume":"185","author":"S Khan","year":"2011","unstructured":"Khan S, Game X, Kalsi V, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185:1344\u20139.","journal-title":"J Urol"},{"key":"68_CR44","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sc.2010.179","volume":"49","author":"CY Chen","year":"2011","unstructured":"Chen CY, Liao CH, Kuo HC. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia. Spinal Cord. 2011;49:659\u201364.","journal-title":"Spinal Cord"},{"key":"68_CR45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11255-010-9873-x","volume":"43","author":"G Chen","year":"2011","unstructured":"Chen G, Liao L. Injections of botulinum toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury. Int Urol Nephrol. 2011;43:655\u201362.","journal-title":"Int Urol Nephrol"},{"key":"68_CR46","first-page":"833","volume":"28","author":"KM Moore","year":"2009","unstructured":"Moore KM, Hirst G, Emery S, et al. Double blind, placebo controlled, randomised, cross over study of trigone specific injections of botulinum toxin B for treating patients with idiopathic detrusor overactivity refractory to other conservative treatments (Abstract number 209). Neurourol Urodyn. 2009;28:833\u20134.","journal-title":"Neurourol Urodyn"},{"key":"68_CR47","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/j.1464-410X.2010.09791.x","volume":"107","author":"X Gam\u00e9","year":"2010","unstructured":"Gam\u00e9 X, Khan S, Panicker JN, et al. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. BJU. 2010;107:1786\u201392.","journal-title":"BJU"},{"key":"68_CR48","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2007.08.039","volume":"53","author":"X Gam\u00e9","year":"2008","unstructured":"Gam\u00e9 X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol. 2008;53:613\u20138.","journal-title":"Eur Urol"},{"key":"68_CR49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0090-4295(01)01637-5","volume":"59","author":"KE Andersson","year":"2002","unstructured":"Andersson KE. Bladder activation: afferent mechanisms. Urology. 2002;59:43\u201350.","journal-title":"Urology"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0068-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0068-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0068-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T12:12:15Z","timestamp":1688299935000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0068-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,18]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["68"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0068-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,18]]}}}